Regeneron gets a European reprieve
The EU recommendation for odronextamab comes after a US rejection in March.
EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
FDA knocks back Regeneron’s CD20 T-cell engager
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Adicet pivots
After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.
Cellular Biomedicine draws a line under its past
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.
ASH 2023 – Regeneron defends its bispecifics
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
